Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zimberelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zimberelimab overview

Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that belongs to a class of immuno-oncology agents. It is formulated as injectable solution for intravenous drip route of administration. Zimberelimab is indicated for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).

GLS-010 (AB-122) is under development for the treatment of metastatic cervical cancer, metastatic castrate resistant prostate cancer (mCRPC), locally advanced/metastatic pancreatic cancer, glioblastoma multiforme (GBM), recurrent glioblastoma multiforme (GBM), rectal cancer, gastric cancer, esophageal cancer, non-small-cell lung cancer, urothelial cancer, colorectal cancer (CRC), pancreatic ductal adenocarcinoma, liver cancer, nasopharyngeal cancer,  peripheral T lymphoma, natural killer cell lymphoma, bile duct cancer, metastatic melanoma, cervical cancer, multiple myeloma (Kahler disease), non-Hodgkin lymphoma, diffuse large B-cell lymphoma, adenocarcinoma of the gastroesophageal junction, hepatocellular cancer, bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gall bladder cancer. The drug candidate is a humanized monoclonal antibody administered through intravenous route. It acts by targeting PD-1 and is developed based on OmniRat technology platform.
The drug candidate is under development for the treatment of breast cancer, ovarian cancer, gastroesophageal cancer, squamous cell carcinoma of the head and neck, Merkel cell carcinoma, melanoma, bladder cancer, endometrial cancer and renal cell carcinoma.

Arcus Biosciences overview

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer, ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US.

For a complete picture of Zimberelimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.